Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.

@article{Pinheiro2001DrugMO,
  title={Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.},
  author={Jo{\~a}o Paulo Vieira Pinheiro and Hans Josef Mueller and Dirk Schwabe and Martin Gunkel and J Casimiro da Palma and G{\"u}nter H R Henze and V von Sch{\"u}tz and M Winkelhorst and Gudrun Wuerthwein and Joachim Boos},
  journal={British journal of haematology},
  year={2001},
  volume={113 1},
  pages={115-9}
}
Use of asparaginase (ASNase) in the treatment of relapsed childhood acute lymphoblastic leukaemia (ALL) is associated with a high rate of hypersensitive reactions. 'Silent' inactivation may additionally reduce treatment intensity. Therefore, PEG-ASNase (Oncaspar), a polyethylene glycol conjugate of the native Escherichia coli-ASNase, was introduced into the Berlin-Frankfurt-Münster (BFM) 96 treatment protocol for relapsed ALL under drug monitoring conditions. A single i.v. dose of 500 IU/m2 PEG… CONTINUE READING